The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: is it the same in all settings?
Simple Summary This review explores the use of hematopoietic stem cell transplantation
(HSCT) as a treatment option for chronic myeloid leukemia (CML) patients. While CML …
(HSCT) as a treatment option for chronic myeloid leukemia (CML) patients. While CML …
The expanding CML treatment landscape: an introspective commentary
JH Lipton - Blood Cancer Journal, 2023 - nature.com
The article by Abdelmagid and co-authors on real-world experience with ponatinib that
accompanies this editorial is interesting. There are three points to take from this. First, it …
accompanies this editorial is interesting. There are three points to take from this. First, it …
Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms
M Kaehler, N von Bubnoff, I Cascorbi… - Frontiers in …, 2024 - frontiersin.org
Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into
different subtypes based on the molecular aberration in the affected cell population …
different subtypes based on the molecular aberration in the affected cell population …
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and …
S Marcé, A Méndez, B Xicoy, N Estrada… - Journal of Clinical …, 2024 - mdpi.com
e13a2 and e14a2 are the most frequent transcript types of the BCR:: ABL1 fusion gene in
chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to …
chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to …
Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
Dasatinib is a potent second-generation tyrosine kinase inhibitor (TKI) used as a first-line
treatment option for patients with chronic myeloid leukemia (CML). Currently, dose …
treatment option for patients with chronic myeloid leukemia (CML). Currently, dose …
[PDF][PDF] Perfil demográfico e de resposta molecular dos pacientes com Leucemia Mieloide Crônica em tratamento com inibidores de tirosinoquinase na Fundação …
RS Abreu - 2023 - pos.uea.edu.br
RESUMO A Leucemia Mieloide Crônica (LMC) é uma neoplasia de células tronco
hematopoiéticas causada por uma translocação recíproca entre os cromossomos 9; 22 que …
hematopoiéticas causada por uma translocação recíproca entre os cromossomos 9; 22 que …
[PDF][PDF] Contribution of Molecular Biology in the Diagnosis and Follow-Up of Chronic Myeloid Leukemia
H Bennani, A El Ouarradi, H Lazrek, H Yahyaoui… - SAS J Med, 2023 - saspublishers.com
Background: The advent of tyrosine kinase inhibitors and the evolution of molecular biology
techniques have revolutionized the management and outcome of patients with chronic …
techniques have revolutionized the management and outcome of patients with chronic …